CSF biomarker discovery using label-free nano-LC-MS based proteomic profiling: technical aspects.

Area of Science:

• Neuroscience
• Proteomics
• Biochemistry

Background:

• Cerebrospinal fluid (CSF) analysis is crucial for diagnosing and monitoring brain disorders.
• Proteomic profiling of CSF holds potential for identifying disease biomarkers.
• Existing methods may require depletion of abundant proteins, complicating analysis.

Purpose of the Study:

• To develop and validate a label-free LC-MS strategy for CSF proteomic analysis.
• To establish a robust protocol for quality control and sample replication.
• To identify potential biomarkers for schizophrenia in CSF.

Main Methods:

• A label-free liquid chromatography-mass spectrometry (LC-MS) approach was employed.
• The protocol included stringent quality control and sample replication steps.
• Pattern recognition methods were adapted for variation detection and biomarker identification.

Main Results:

• The strategy was tested on 20 CSF samples (10 healthy, 10 schizophrenia).
• A distinct proteomic difference was observed between healthy volunteers and schizophrenia patients.
• 77 proteins were confidently detected, including seven novel identifications, without protein depletion.

Conclusions:

• The developed label-free LC-MS strategy offers a simple and controlled method for CSF biomarker discovery.
• This approach facilitates the identification of potential diagnostic and monitoring markers for brain disorders.
• The findings highlight the utility of CSF proteomic profiling in understanding neurological conditions like schizophrenia.